摘要
目的探讨新赛斯平治疗再生障碍性贫血的疗效和安全性。方法选择收治的再生障碍性贫血患者62例,随机分为两组,每组31例。对照组患者给予康力龙治疗,分3次口服。治疗组患者在对照组基础上给予新赛斯平治疗,分2次口服。定期复查血常规、肝肾功能,观察并记录输注红细胞及血小板的变化以及疗效。结果治疗6个月后,治疗组患者的白细胞计数、血红蛋白和血小板均有显著改善(P<0.05);总有效率对照组为51.67%,治疗组为74.19%,两组差异有统计学意义(P<0.05)。两组均出现血清病、肺部感染、皮疹及肝功能受损等轻微不良反应,经对症治疗后症状消失,不影响疗效。结论新赛斯平治疗再生障碍性贫血疗效显著、安全性好,值得临床推广。
Objective To explore the efficacy and safety of New Cyspin in the treatment of aplastic anemia. Methods Sixty-two pa- tients with aplastic anemia in our hospital were selected,including 33 males and 29 females,the mean age （35.2±6. 9） years old,and divided into 2 groups with 31 cases in each group. The control group was given oral stanozolol,3 times daily. On this basis,the treat- ment group was given oral New Cyspin, twice daily. The blood, liver and kidney function were re- examined at regular intervals. The changes of RBC and platelet transfusion and the curative effects were observed and recorded. Results After 6- month treatment, WBC count, hemoglobin and platelet in the treatment group were significantly improved, showing statistical difference as compared with before treatment （P 〈0.05）. The total effective rate was 51.67% in the control group and 74. 19% in the treatment group,the difference be- tween the two groups had statistical significance （P 〈 0.05）. Mild adverse reactions such as serum disease, pulmonary infection, skin rash and liver function damage occurred in both two groups and disappeared after the symptomatic treatment without influencing the treatment efficacy. Conclusion New Cyspin has significant efficacy and good safety for treating aplastic anemia, and deserves to be pro- moted in clinical use.
出处
《中国药业》
CAS
2013年第6期17-18,共2页
China Pharmaceuticals
